DNAPrint genomics to Present at Library of Congress Symposium SARASOTA, Fla., May 13 /PRNewswire-FirstCall/ -- DNAPrint genomics (OTC:DNAP) (BULLETIN BOARD: DNAP) today announced that it will present at a U.S. Library of Congress Symposium in Washington exploring the hypothesis that North America was "discovered" by the Chinese prior to contact with Europeans. The symposium on Monday, May 16 is entitled, "The Significance of Admiral Zheng He's Voyages (1405-1433)." The symposium observes the 600th anniversary of the first voyage of Chinese Admiral Zheng He, a Chinese explorer. Carrying out the orders of Zhu Di, the third emperor of the Ming Dynasty, Zheng He undertook a series of expeditions between 1405 and 1433 with a fleet of 200 ships and a crew of 28,000 men, the largest maritime expeditions in world history. The symposium will feature Zheng He scholars and experts who will discuss the latest discoveries about various aspects of the expeditions. Among the speakers will be Gavin Menzies, retired British Royal Navy Captain and the author of "1421: The Year China Discovered America," published in January 2003. "The Chinese hypothesis has been hotly debated since it was originally proposed in Capt. Menzies' book," stated Tony M. Frudakis, Ph.D., the founder and Chief Scientific Officer of DNAPrint genomics, who will be a presenter at the symposium. "With DNAPrint's expertise and technology for measuring genetic ancestry and an extensive Native American DNA sample collection, we hope to bring a unique perspective to the discussion." About DNAPrint genomics, Inc. DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company's ANCESTRYbyDNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit http://www.dnaprint.com/ . Forward-Looking Statements All statements in this press release that are not historical are forward- looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Company Contact: Richard Gabriel President and CEO 941-366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848 DATASOURCE: DNAPrint genomics, Inc. CONTACT: Richard Gabriel, President and CEO, DNAPrint genomics, Inc., +1-941-366-3400; or Ron Stabiner, The Wall Street Group, Inc., +1-212-888-4848, for DNAPrint genomics, Inc. Web site: http://www.dnaprint.com/

Copyright